Company AnnouncementTransaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolioTransaction anticipated to be accretive to Genmab’s EBITDA by end ...
KUALA LUMPUR, MY / ACCESS Newswire / December 12, 2025 / Agape ATP Corporation (NASDAQ:ATPC) ("ATPC" or "the Company") a provider of health and wellness products and sustainable energy solutions, ...
Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital gonorrhea.Positive study results are a ...
Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December ...
- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and ...
Adjourns 2025 Annual Meeting of StockholdersUrges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ...
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation ...
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company’s senior ...
LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 11, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into ...
Eating Bacteria Market in China" has been added to ResearchAndMarkets.com's offering.The global plastic-eating bacteria market is expected to reach an estimated $500 thousand by 2031, with a CAGR of ...
The "Biomimetic Plastic Material Market in China" has been added to ResearchAndMarkets.com's offering.The global biomimetic plastic material market is expected to reach an estimated $10.5 billion by ...
Concise regulatory statusPivotal trialOveporextonTakedaNarcolepsy (orexin‑2 agonist)US, EU, JPPhase III completed; filings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback